Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MiMedx gets access to SaluMedica's Salubria tech for SpineMedica

This article was originally published in Clinica

Executive Summary

SpineMedica, a firm that develops treatments for spinal disorders and chronic back pain, has gained access to SaluMedica's Salubria hydrogel technology following a license agreement between the biomaterials specialist and SpineMedica's parent company MiMedx. Under the terms of the deal, MiMedx will have exclusive worldwide rights to use Salubria as a surgical sheet for both internal and external applications. The material, which is designed to have similar properties to human tissue but with increased wear resistance, can be used in surgery for preventing scars and as an anti-adhesive. SpineMedica, based in Atlanta, Georgia, will initially develop the technology for a vessel guard to protect blood vessels during anterior spinal surgeries. Smyrna, Georgia-based SaluMedica will receive upfront 400,000 MiMedx shares for the licence, and an additional 600,000 shares if MiMedx (Tampa, Florida) achieves certain sales milestones by June 2013.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046641

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel